Fleming RM, Boyd LB: The longitudinal effects of fenfluramine-phentermine use. Angiology58:353-359, 2007.
2.
Weissman NJ, Panza JA, Tighe JF, et al: Specificity of Doppler echocardiography for the assessment of changes in valvular regurgitation: comparison of side-by-side versus serial interpretationJ Am Coll Cardiol 37:1614-1621, 2001
3.
Gottdiener JS , Panza JA, St John Sutton M., et al: Testing the test: the reliability of echocardiography in the sequential assessment of valvular regurgitation. Am Heart J144:115-121, 2002.
4.
Connolly HM, Crary JL, McGoon MD, et al: Valvular heart disease associated with fenfluramine-phentermine . N Engl J Med337:581-585, 1997.
5.
Zanettini R. , Antonini A., Gatto G., et al: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med356:39-46, 2007.
6.
Jagroop I., Mikhailidis D.: An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets11:161-165, 2000.
7.
Fitzgerald LW , Burn TC, Brown BS, et al: Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine . Mol Pharmacol57:75-81, 2000.
8.
Rothman RB, Baumann MH, Savage JE, et al: Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications . Circulation102:2836-2841, 2000 .
